GAMMA Investing’s Aclaris Therapeutics ACRS Stock Holding History

GAMMA Investing’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$9.76K	Buy	1,856 +836	+82%	+$4.77K	﹤0.01%	3345
2026 Q2	$5.4K	Hold	1,020	–	–	﹤0.01%	3435
2026 Q1	$3.83K	Buy	1,020 +791	+345%	+$2.67K	﹤0.01%	3467
2025 Q4	$689	Buy	+229	New	+$579	﹤0.01%	3865

Other funds holding ACRS

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's ACRS Position: Q3 2026 in Review

GAMMA Investing increased its Aclaris Therapeutics (ACRS) stake by 82% in Q3 2026, buying an estimated $4.77K and bringing the position to 1,856 shares worth $9.76K. The position accounts for ﹤0.01% of the portfolio, ranked #3345.

GAMMA Investing first reported a position in ACRS in Q4 2025 and has held it in 4 quarters since. 3 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.

GAMMA Investing held 1,856 shares of Aclaris Therapeutics worth $9.76K as of Q3 2026.
GAMMA Investing bought 836 Aclaris Therapeutics shares in Q3 2026, an estimated $4.77K.
Aclaris Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3345 holding.
GAMMA Investing first reported a position in Aclaris Therapeutics in Q4 2025 and has held it in 4 quarters since.
3 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.